Status:
UNKNOWN
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavi...
Eligibility Criteria
Inclusion
- 18-65 years of age, inclusive
- primary diagnosis of chronic HCV infection, genotype 1
- Interferon-based treatment-naïve
- Body Mass Index of 18 to 30, inclusive
Exclusion
- patients previously treated with Interferon-based therapy
- patients with diabetes mellitus
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00332176
Start Date
June 1 2006
End Date
December 1 2008
Last Update
April 8 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Liver and Intestinal Research Centre
Vancouver, British Columbia, Canada, V5Z 1H2
2
Cantest
Vancouver, British Columbia, Canada, V5Z 1H6
3
Biovail Contract Research
Toronto, Ontario, Canada, M1L 4S4